ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Protocol ID
J1S-MC-JV01
Disease (Sub Disease)
Desmoplastic Small Round Cell Tumor
Diagnosis Stage
Relapsed/refractory
Sponsor
Eli Lilly and Company
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months to 29 Years
International registry ID's
NCT04145349
Back to Registry
Study Title A Randomized Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed Recurrent or Refractory Desmoplastic Small Round Cell Tumor
Protocol ID J1S-MC-JV01
Disease (Sub Disease) Desmoplastic Small Round Cell Tumor
Diagnosis Stage Relapsed/refractory
Sponsor Eli Lilly and Company
Links https://clinicaltrials.gov/ct2/show/NCT04145349
Trial Status Closed to Recruitment
Trial Open Date 02/08/2021
Study Type Treatment
Phase Phase 1/2
Age Eligibility 12 Months to 29 Years
International registry ID's NCT04145349

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168